Harvard Bioscience Inc.
Find Ratings ReportsHARVARD BIOSCIENCE INC's gross profit margin for the third quarter of its fiscal year 2023 has increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. HARVARD BIOSCIENCE INC has weak liquidity. Currently, the Quick Ratio is 0.84 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 3.20% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY23 | Q3 FY22 |
---|---|---|
Net Sales ($mil) | 25.36 | 26.92 |
EBITDA ($mil) | 0.85 | -0.1 |
EBIT ($mil) | -0.93 | -2.03 |
Net Income ($mil) | -1.24 | -3.41 |
Balance Sheet | Q3 FY23 | Q3 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 5.34 | 5.14 |
Total Assets ($mil) | 139.74 | 147.01 |
Total Debt ($mil) | 45.29 | 56.91 |
Equity ($mil) | 74.29 | 71.98 |
Profitability | Q3 FY23 | Q3 FY22 |
---|---|---|
Gross Profit Margin | 59.71 | 51.92 |
EBITDA Margin | 3.33 | -0.36 |
Operating Margin | -3.68 | -7.55 |
Sales Turnover | 0.81 | 0.8 |
Return on Assets | -2.33 | -4.68 |
Return on Equity | -4.39 | -9.57 |
Debt | Q3 FY23 | Q3 FY22 |
---|---|---|
Current Ratio | 2.09 | 2.43 |
Debt/Capital | 0.38 | 0.44 |
Interest Expense | 0.88 | 0.75 |
Interest Coverage | -1.06 | -2.71 |
Share Data | Q3 FY23 | Q3 FY22 |
---|---|---|
Shares outstanding (mil) | 42.69 | 41.66 |
Div / share | 0.0 | 0.0 |
EPS | -0.03 | -0.08 |
Book value / share | 1.74 | 1.73 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 81617.0 | 88662.0 |
HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 2.47 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 23.59. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, HARVARD BIOSCIENCE INC proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HBIO NM | Peers 53.34 | HBIO 14.70 | Peers 44.47 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. HBIO's P/E is negative making this valuation measure meaningless. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. HBIO is trading at a significant discount to its peers. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
HBIO 14.79 | Peers 26.06 | HBIO NA | Peers 1.95 | |||||||||||||||||||||
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations. HBIO is trading at a significant discount to its peers. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
HBIO 2.47 | Peers 23.59 | HBIO 52.95 | Peers 123.02 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. HBIO is trading at a significant discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, HBIO is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
HBIO 1.63 | Peers 14.13 | HBIO -4.62 | Peers 27.20 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. HBIO is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. HBIO significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||